[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urti\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urti":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100642225","phase-2-a-novel-cold-and-flu-herbal-blend-for-reducing-the-duration-and-severity-of-the-common-cold-100642225",false,"NCT07642648","A Novel Cold and Flu Herbal Blend for Reducing the Duration and Severity of the Common Cold","A Randomized Blinded Controlled Trial Evaluating the Efficacy of a Novel Herbal Cold and Flu Blend in Reducing the Duration and Severity of Symptoms of the Common Cold","NOURTI","Inclusion Criteria:\n\n* Adults aged 18-65 years living in Australia\n* Individuals with a history of recurrent Upper Respiratory Tract infections (URTI) (at least one episode per year)\n* Able to provide informed consent\n* Generally healthy\n* Agree to not participate in another clinical trial while enrolled in this trial\n* Agree to maintain their usual daily activities without significant changes. This includes not changing their current diet or stopping\u002Fstarting a new exercise regimen during entire study period\n* Females of childbearing potential must use a prescribed form of birth control (e.g. oral contraceptive)\n\nExclusion Criteria:\n\n* Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, autoimmune conditions, neurological disorders such as multiple sclerosis.\n* Unstable illness e.g., changing medication\u002Ftreatment.\n* BMI \\\u003C18.5, \\>30\n* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.\n* Individuals with chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease).\n* Active smokers, nicotine use (including vaping\u002Fe-cigarettes) or drug (prescription or illegal substances) abuse\n* Current alcohol use (\\>21 alcoholic drinks week)\n* Allergic to any of the ingredients in the active or placebo formula\n* Allergic to plants in the Asteraceae family\n* Pregnant or lactating woman\n* Regular use of medications that would affect the immune and\u002For the inflammatory response e.g. antihistamines, anti-inflammatories, immunosuppressants, steroids excluding topical steroid use.\n* Use of anticoagulant medications such as warfarin.\n* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month\n* Participants with allergic rhinitis\n* Regular use of antihistamines\n* Individuals deemed unsuitable for participation by the Principal Investigator (PI) of this study.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},300,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The aim of this study is to evaluate the efficacy of a Novel Herbal Cold \\& Flu Blend in reducing the duration of symptoms of the common cold. The secondary objective is to assess whether the investigational product reduces the severity of symptoms. Participants will be enrolled for 16 weeks, during this period they will take the assigned study product when they experience URTI symptoms.",[29,30],"URTI","Common Cold","NOT_YET_RECRUITING","2026-06-07",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":23},"2026-07",{"date":39,"type":23},"2027-12",{"name":41,"class":42},"RDC Clinical Pty Ltd","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100613120","assessement-of-effectiveness-of-seawater-nasal-sprays-on-sinonasal-symptoms-100613120","NCT07262450","Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","Real-word Study to Assess Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","SeaBridge","Inclusion criteria:\n\n* Subject's age and medical condition in compliance with the intended use and population\n* Subjects who, from the investigator's judgement, should benefit from nasal wash in accordance with routine medical practice\n* Subjects with at least two nasal symptoms of intensity ≥ 3 (6 modalities intensity SNOT-22 rating-scale) among the following:\n\n  * Nasal blockage\u002Fnasal congestion\u002F stuffy nose;\n  * Runny nose;\n  * Need to blow\u002Fclear the nose;\n  * Sneezing;\n  * Thick nasal discharge\u002Fsecretions;\n  * Decreased sense of smell \u002Ftaste (replaced by \"noisy breathing\u002Fmouth breathing\" for infants)\n* Subjects with impaired nasal breathing (score ≥ 3, 6-modalities intensity rating-scale), induced by the presence of nasal symptoms\n* For acute indications (only): subjects with symptoms started not later than 72 hours prior to enrolment (Day 0).\n* For allergic rhinitis indication: perennial allergic rhinitis with and without seasonal allergic rhinitis\n* For post-surgery indication: septoplasty and rhinoseptoplasty.\n* Subject\u002Fparent willing to perform nasal wash following advices received from HCPs.\n* Subjects (or parents for babies and children) agreeing to follow the study requirements during the whole study period (up to 3 months).\n* Subject (or parent for baby and children) able to understand verbal and written local language and in capacity to fill-in questionnaire by himself.\n* Subject having daily access to internet to answer online questionnaire.\n* Subject or Parent\u002Flegal guardian of the subject has given freely and expressly her\u002Fhis informed consent.\n* Subject affiliated to the health social security system or beneficiary of an equivalent system\n\nNon-inclusion criteria:\n\n* Subject with contraindications according to each IFU.\n* Hypersensitivity or known allergy to any component of the investigational products.\n* Subject taking part in another clinical study or being in the exclusion period of another clinical study.\n* Subject already using nasal wash to manage his nasal symptoms.\n* Subject already included once in the study.\n* Subject with a member of his household already included in the study if still in the follow-up phase.\n* Subject deprived of liberty by administrative or judicial decision or under legal guardianship.","15 Days",{"count":53,"type":23},1065,[55],"NA","The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.\n\nThe main questions it aims to answer are:\n\n* Efficacy,\n* Safety,\n* Usage,\n* Satisfaction, in real-life usage among infants, children, adults and pregnant or breastfeeding women suffering from acute and chronic sinonasal pathologies. The 4 medical devices under investigation will be used in accordance with their intended use, target populations and medical indications.",[29,58,59,60,61,62],"Bronchiolitis","COVID - 19","Allergic Rhinitis","Chronic Rhinosinusitis (CRS)","Post-surgery","RECRUITING","2025-12-01",{"date":66,"type":35},"2025-12-03",{"date":68,"type":35},"2025-08-27",{"date":70,"type":23},"2026-08",{"name":72,"class":42},"Laboratoire de la Mer",32]